Printer Friendly

CELOX FILES WITH FDA FOR NEW REGISTRATION STATUS TO BECOME A MEDICAL DEVICE COMPANY -- WILL ALLOW COMPANY TO ENTER NEW BIOTECH MARKETS

 MINNEAPOLIS, March 22 /PRNewswire/ -- Celox Corporation (NASDAQ: CELX), a manufacturer of cell biology products, has filed an initial registration with the Food & Drug Administration (FDA) to become a medical device company. This status will allow Celox to sell its products to diagnose human disease.
 "This is a significant advancement for Celox," said Milo R. Polovina, president and CEO. "We will be able to pursue entirely new markets."
 Since its beginning, Celox has been a pioneer in the research and development of non-human and non-animal serum cell growth products.
 The company has already been approved as a vendor under a GSA (General Services Administration) government contract with the pharmaceutical products division. The contract is effective through 1996.
 By receiving the contract, Celox's products are qualified for use by numerous governmental institutions, including the National Institutes of Health, National Cancer Institute, Centers for Disease Control, VA Medical Centers and U.S. Department of Agriculture.
 "We have already received several initial orders under the GSA contract," said Polovina.
 In addition, Celox recently announced several distribution agreements to market its products internationally, including Funakoshi Co., Ltd., in Japan; TechGen International in Europe; and Intermountain Scientific Corporation in 14 western U.S. states.
 Celox is a biotechnology company that researches, develops, manufactures and markets cell biology products used in the growth of human and other types of cells. These specialized products are used in researching major health problems such as AIDS, cancer and cardiovascular disease.
 -0- 3/22/93
 /CONTACT: Milo R. Polovina, president/CEO of Celox Corporation, 612-933-2616; or Gail D. Shore of Shore to Shore Communications, 612-925-6102, for Celox/
 (CELX)


CO: Celox Corporation ST: Minnesota IN: MTC SU:

KH -- MN007 -- 8188 03/22/93 11:24 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 22, 1993
Words:284
Previous Article:WICAT SELECTED BY CAE-LINK TO PROVIDE AIR NATIONAL GUARD CBT SYSTEM
Next Article:15 KEY APPLICATIONS RUN AT INDUSTRY-LEADING SPEEDS ON CRAY RESEARCH SUPERCOMPUTER
Topics:


Related Articles
INCREASED SALES MARKED 1993 FOR CELOX CORPORATION
NEW STUDY SHOWS FDA INEFFICIENCY COSTS CALIFORNIA THOUSANDS OF BIOMEDICAL JOBS, NEARLY ONE BILLION IN LOST SALARIES
Center For Health Technologies Grants Pioneer Services Provisional Acceptance To The Center's Incubator Network
CELOX Laboratories, Inc. Announces Research Agreement with University of Minnesota.
Possis Medical, Inc. Raises $6.0 Million in New Private Placement Financing.
Cook Incorporated Forms Dedicated Tissue Engineered Products Group.
Reproductive tissue, human cellular product establishments have 60 days to register with FDA.
BSD Medical Corporation Raises $2 Million in Private Placement.
Vascular Solutions Files Shelf Registration Statement.
NMT Medical Voluntarily Withdraws CardioSEAL(R) PFO HDE and Receives FDA Approval for New STARFlex(R) PFO IDE Study.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters